Discover Our Chronic Liver Disease Testing

While attending The Liver Meeting® 2019
November 9–11, visit us at booth #624.*

*The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases

Discover How Our Chronic Liver Disease Testing Supports Clinical Practice

As the world leader in the diagnosis and treatment of gastrointestinal conditions for the last 28 years, we know the importance of laboratory testing in a patient's care. Our disease-specific tests are clinically reinforced, cost-effective, and patient care-driven.

In addition to the latest testing, when you partner with us, you extend your network to include some of the world's leading gastroenterology experts. Our clinicians, laboratorians, and genetic counselors are available for consultation seven days a week to provide interpretive expertise and support.

Mayo Clinic Voices at the Conference

Chronic Liver Disease: Full-Spectrum Testing to Identify the Underlying Cause and Risk for Progression to Cancer

Mayo Clinic Laboratories offers the only comprehensive liver disease testing menu developed by clinical experts to help health care providers determine the underlying cause and rule out other causes for the disease.

Featured Booklet


Determine Levels of Fibrosis and Necroinflammatory Activity

FibroTest-ActiTest can be used as a first-line screen to assess the condition of the liver using two diagnostic scores—one for liver fibrosis and one for liver inflammation—based on component tests for six biomarkers.

Featured Test

Advantages of FibroTest-AcitiTest

  • The most reliable biomarker test, applicable to the largest number of patients (98%).
  • Offers the best performance of any test, at all stages of fibrosis, from a healthy liver to cirrhosis.
  • The noninvasive test that is least affected by known risk factors for false positives and false negatives.
  • Easy-to-read report shows both proprietary FibroTest and ActiTest scores and METAVIR fibrosis stage and activity grade.

Confidently Evaluate for NASH, Steatosis, and Fibrosis/Cirrhosis with One Standard Blood Sample

In the United States, 80 to 100 million people live with NAFLD. More than 25% of these patients will go on to develop NASH. Using a simple blood sample, this test combines 10 standard biomarkers into five scores to provide a complete assessment of the condition of the liver and the five main causes of liver disease including hepatic steatosis, NASH, alcoholic steatohepatitis, fibrosis, and liver inflammation.

Featured Test

Additional Resources


Hepatitis B, C, and E

To expedite diagnosis and treatment of chronic viral hepatitis, our clinical experts have developed specific testing algorithms to guide the test-ordering process. This approach takes the guesswork out of ordering, and it focuses on test utilization, saving your institution time and money with better patient outcomes from faster turnaround times and treatment options.

Featured Tests

Diagnosis, Detection, and Confirmation
Hepatitis B
Hepatitis B Surface Antigen, Serum (Mayo ID: HBAG)

Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum (Mayo ID: HBAB)

Hepatitis B Core Total Antibodies, Serum (Mayo ID: HBC)

Hepatitis C
Hepatitis C Antibody with Reflex to HCV RNA by PCR, Serum (Mayo ID: HCVDX)

Hepatitis C Antibody Screen with Reflex to HCV RNA by PCR, Serum (Mayo ID: HCSRN)

Hepatitis E
Hepatitis E Virus IgG Antibody, Serum (Mayo ID: HEVG)

Hepatitis E Virus IgM Antibody Screen with Reflex to Confirmation, Serum (Mayo ID: HEVM)
Hepatitis B Virus (HBV) DNA Detection and Quantification by Real-Time PCR, Serum (Mayo ID: HBVQN)

Hepatitis C Virus (HCV) RNA Detection and Quantification by Real-Time Reverse Transcription-PCR (RT-PCR), Serum (Mayo ID: HCVQN)

Hepatitis C Virus Genotype, Serum (Mayo ID: HCVG)

Additional Resources


Early Identification of Underlying Genetic Causes to Prevent Organ Damage

Identifying underlying genetic disorders plays an important role in the treatment and care of patients with liver disease. Appropriate use of screening tests in routine clinical practice can:

  • Rule out possible causes of liver disease.
  • Assist in early identification and treatment of genetic liver diseases to prevent terminal organ damage.

Featured Tests

Alpha-1-Antitrypsin (A1A) Deficiency
Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum (Mayo ID: A1ALC)

SERIPINA1 Gene, Full Gene Analysis (Mayo ID: SERPZ)

Hemochromatosis HFE Gene Analysis, Blood (Mayo ID: HFE)

Wilson Disease
First-Tier Screening
Ceruloplasmin, Serum (Mayo ID: CERS)

Copper Tissue
Copper, Liver Tissue (Mayo ID: CUT) 

Genetic Testing to Confirm Diagnosis and Identify At-Risk Family Members
Wilson Disease, Full Gene Analysis (Mayo ID: WDZ)

Lysosomal Acid Lipase Deficiency (LAL-D)

Late-onset LAL-D is likely underdiagnosed and frequently identified after liver pathology reveals findings similar to NAFLD or NASH. Early diagnosis of LAL-D is critical to stopping the progression of the disease, as studies have shown that nearly 50% of pediatric and adult LAL-D patients progress to fibrosis, cirrhosis, or liver transplantation within three years of first clinical manifestation.

Featured Test


Comprehensive Panel to Help Diagnose the Two Most Common Forms of Autoimmune Liver Disease

Autoimmune liver diseases result from inflammatory immune reactions that damage hepatocytes or cholangiocytes. Due to the variance in autoimmune disease forms (which include autoimmune hepatitis [AIH], primary biliary cirrhosis [PBC], and primary sclerosis cholangitis [PSC]), many patients can be misdiagnosed. Early and accurate diagnosis can lead to better treatment outcomes for patients, namely, the avoidance of liver transplants.

Our panel evaluates smooth muscle antibodies (SMA), antinuclear antibodies (ANA), and antimitochondrial antibodies (AMA) for patients with:

  • Suspected autoimmune liver disease, specifically type 1 AIH or PBC.
  • Liver disease of unknown etiology.

Featured Test

Celiac disease may also be associated with severe forms of liver disease and/or coexist with other autoimmune liver diseases. Isolated hypertransaminasemia, with mild or nonspecific histologic changes in the liver biopsy (also known as "celiac hepatitis") is the most frequent presentation of liver injury in celiac disease. Histologic changes and liver enzymes reverse to their normal states after treatment with a gluten-free diet in most patients.

Featured Test

Additional Resources


Assess Cancer Risk and Identify Opportunities for Increased Surveillance

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be treated effectively in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and stages when the disease is less responsive to therapies. Laboratory testing and imaging can identify at-risk patients needing increased surveillance to help aid in early diagnosis.

14. Data collected for μTAS Wako i30 Analyzer and Test Systems US FDA 510(k) Submission.

To speak with a clinical specialty representative and learn more about how our testing can integrate with your practice, call 800-553-1710.

Emily Linginfelter

Emily Linginfelter is a Marketing Associate at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Emily has worked at Mayo Clinic since 2018.